Metronomic Chemotherapy Enhances Antitumor Effects of Cancer Vaccine by Depleting Regulatory T Lymphocytes and Inhibiting Tumor Angiogenesis
Open Access
- 1 June 2010
- journal article
- Published by Elsevier BV in Molecular Therapy
- Vol. 18 (6), 1233-1243
- https://doi.org/10.1038/mt.2010.34
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytesClinical and Experimental Immunology, 2007
- Intensive Dose-Dense Compared With High-Dose Adjuvant Chemotherapy for High-Risk Operable Breast Cancer: Southwest Oncology Group/Intergroup Study 9623Journal of Clinical Oncology, 2007
- Depletion of CD4+CD25+ regulatory T cells enhances interleukin‐2‐induced antitumor immunity in a mouse model of colon adenocarcinomaCancer Science, 2007
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- Chimeric DNA Vaccine Reverses Morphine-Induced Immunosuppression and TumorigenesisMolecular Therapy, 2006
- The Requirement of Multimodal Therapy (Vaccine, Local Tumor Radiation, and Reduction of Suppressor Cells) to Eliminate Established TumorsClinical Cancer Research, 2005
- CD8+ T cells, NK cells and IFN-γ are important for control of tumor with downregulated MHC class I expression by DNA vaccinationGene Therapy, 2003
- Repeated DNA Vaccinations Elicited Qualitatively Different Cytotoxic T Lymphocytes and Improved Protective Antitumor EffectsJournal of Biomedical Science, 2002
- Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.JCI Insight, 1998
- New Natural Products in Cancer ChemotherapyThe Journal of Clinical Pharmacology, 1990